Skip to main content
4D Molecular Therapeutics, Inc. logo

4D Molecular Therapeutics, Inc. — Investor Relations & Filings

Ticker · FDMT ISIN · US35104E1001 US Manufacturing
Open in API
Filings indexed 372 across all filing types
Latest filing 2020-12-04 Regulatory Filings
Country US United States of America
Listing US FDMT

About 4D Molecular Therapeutics, Inc.

https://4dmoleculartherapeutics.com/

4D Molecular Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on inventing and developing genetic medicines to treat large-market diseases with unmet medical needs. The company utilizes its proprietary Therapeutic Vector Evolution platform, which harnesses the power of directed evolution, to create customized and optimized adeno-associated virus (AAV) vectors. These engineered vectors are designed for targeted delivery and enhanced therapeutic efficacy. 4DMT's clinical pipeline is concentrated on developing transformative products for serious conditions in ophthalmology, such as wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), and in pulmonology, including cystic fibrosis.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2020
Regulatory Filings Classification · 90% confidence The provided document text appears to be encoded or encrypted data rather than readable text. There are no discernible keywords, regulatory references, fiscal period dates, or document titles that indicate the nature of the filing. The length is about 15,000 characters, which is substantial, but without readable content or context, it is impossible to classify it as a specific report type such as Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). Given the lack of identifiable information and the fallback rule, the document should be classified as a Regulatory Filing (RNS).
2020-12-04 English
Regulatory Filings 2020
Regulatory Filings
2020-12-02 English
Regulatory Filings 2020
Regulatory Filings Classification · 95% confidence The document is a detailed correspondence letter from a law firm to the SEC regarding a revised Registration Statement on Form S-1 for 4D Molecular Therapeutics, Inc. It discusses responses to SEC staff comments on the draft Registration Statement, including disclosures about product candidates, risk factors, use of proceeds, and other regulatory compliance matters. The document references the Form S-1 registration process, which is related to securities offerings and IPO filings. It is not a financial report, earnings release, or management discussion, but rather a regulatory filing related to the registration statement submission and review process. Therefore, the document fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2020-11-17 English
S-1
Capital/Financing Update Classification · 95% confidence The document is a Form S-1 Registration Statement filed with the SEC, dated November 17, 2020, for 4D Molecular Therapeutics, Inc. It is a registration statement under the Securities Act of 1933, used for initial public offerings (IPOs) or other securities offerings. The text includes detailed information about the company, the offering, risk factors, management, financial data, and other disclosures typical of an S-1 filing. This is not an annual report, earnings release, or any other report type but a registration statement for a securities offering. According to the filing definitions, none of the categories explicitly mention S-1 registration statements, but the closest and most appropriate category for such SEC registration statements related to capital raising is Capital/Financing Update (CAP). Therefore, the document should be classified as CAP with high confidence.
2020-11-17 English
Capital/Financing Update 2020
Capital/Financing Update Classification · 100% confidence The document is a confidential draft registration statement submitted to the SEC on Form S-1, which is used for initial public offerings (IPOs) to register securities under the Securities Act of 1933. It includes detailed information about the company, the offering, risk factors, management, financial data, and other disclosures typical of a registration statement for an IPO. This is not an annual report, earnings release, or any other type of financial or regulatory filing. The Form S-1 is a capital markets filing related to the company's fundraising and securities offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is the actual registration statement, not just an announcement or summary.
2020-10-14 English
RW
Regulatory Filings Classification · 100% confidence The document is a letter addressed to the SEC requesting the withdrawal of a Registration Statement on Form S-1. It states that the company is no longer pursuing an IPO and requests withdrawal of the filing. There are no financial statements, earnings data, or detailed report content. The document is a regulatory communication about a filing withdrawal, not a financial report or announcement of results. It is short (1910 characters) and serves as a formal regulatory filing notice. Therefore, it fits best under Regulatory Filings (RNS).
2020-07-21 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.